Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 4/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7635714 | 0.82 | ATM (0.47) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL16486580 | 0.82 | TSHR (0.58) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL10840160 | 0.82 | HCAR2 (0.44) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL7635675 | 0.81 | ATM (0.42) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL20875236 | 0.80 | ATM (0.60) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL8669692 | 0.80 | ATM (0.60) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL15901752 | 0.80 | ATM (0.47) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL340231 | 0.80 | ATM (0.47) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL7641351 | 0.79 | HCAR2 (0.41) | ATMHCAR2TSHRALDH1A1CYP3A4 | |
| SCHEMBL7629294 | 0.79 | ATM (0.43) | ATMHCAR2TSHRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604658-B2 | Organic silicon compound, surface treatment agent containing same, resin composition containing same, and gel or cured product of same | DOW TORAY CO., LTD. (JP) | 2020-03-31 | — | — | US | disclosed |
| WO-2015022998-A1 | NOVEL ORGANIC SILICON COMPOUND, SURFACE TREATMENT AGENT CONTAINING SAME, RESIN COMPOSITION CONTAINING SAME, AND GEL OR CURED PRODUCT OF SAME | DOW CORNING TORAY CO., LTD. (JP) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604658-B2 | Organic silicon compound, surface treatment agent containing same, resin composition containing same, and gel or cured product of same | ASH2L, RPS7, MRPS27 | ATM 2145/4885HCAR2 1745/4885TSHR 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.